MetaCap

Alterity Therapeutics (ATHE) vs Edesa Biotech (EDSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Edesa Biotech (EDSA) has outperformed Alterity Therapeutics (ATHE) over the past year, gaining 17.6% versus a loss of 56.7%. Over five years, ATHE leads with a -85.4% price change compared with -95.6% for EDSA. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $27.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATHE-56.70%EDSA+17.65%
+1027%+459%-108%
Nov 21, 20251 yearNov 20, 2026
ATHE-85.93%EDSA-95.72%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATHE versus EDSA key metrics
MetricATHEEDSA
Share price$1.52$2.00
Market cap$29.02M$27.02M
1-day change-8.16%-8.05%
YTD return-50.65%+40.85%
1-year return-56.70%+17.65%
5-year return-85.38%-95.63%
EPS (TTM)$-0.90$-1.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-7.19M
52-week high$5.89$20.32
52-week low$1.52$0.72
Distance from 52-week high-74.19%-90.16%
Analyst consensusnonenone
Avg. price target upside+771.71%+716.50%
Average volume89.63K1.45M
Shares outstanding19.09M13.51M
Employees1117
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EDSA has outperformed ATHE by 74.3 percentage points over the past year.

About Alterity Therapeutics

ATHE stock →

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Edesa Biotech

EDSA stock →

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

ATHE vs EDSA FAQ

Which is bigger, Alterity Therapeutics or Edesa Biotech?

Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $27.02M for Edesa Biotech (EDSA).

Which stock has performed better over the past year, ATHE or EDSA?

EDSA returned +17.65% over the past 12 months, compared with -56.70% for ATHE (price return, excluding dividends). Past performance does not predict future results.

Are Alterity Therapeutics and Edesa Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons